P16-45. High avidity CD4+ T cell response directed to an immunodominant Gag epitope in HIV controllers: an ANRS EP36 study

Benoît Vingert, Santiago Perez-Patrigeon, Patricia Jeannin, Olivier Lambotte, Faroudy Boufassa, Fabrice Lemaître, William K. Kwok, Ioannis Theodorou, Jean-François Delfraissy, Jacques Thèze, et al.

Retrovirology

Poster presentation

P16-45. High avidity CD4+ T cell response directed to an immunodominant Gag epitope in HIV controllers: an ANRS EP36 study

B Vingert[6], S Perez-Patrigeon[6], P Jeannin[6], O Lambotte[1], F Boufassa[2], F Lemaître[3], WK Kwok[4], I Theodorou[5], J Delfraissy[1], J Thèze[6] and LA Chakrabarti*[6]

Address: [1]AP-HP, Department of Internal Medicine and Infectious Diseases, Bicêtre Hospital, Le Kremlin-Bicêtre, France, [2]INSERM U822, Bicêtre Hospital, Le Kremlin-Bicêtre, France, [3]G5 Dynamiques des Réponses Immunes, Institut Pasteur, Paris, France, [4]Benaroya Research Institute at Virginia Mason, Seattle, USA, [5]INSERM U543, Pitié-Salpêtrière Hospital, Paris, France and [6]Unité d'Immunogénétique Cellulaire, Institut Pasteur, Paris Cedex 15, France

* Corresponding author

from AIDS Vaccine 2009
Paris, France. 19–22 October 2009

Published: 22 October 2009

Retrovirology 2009, **6**(Suppl 3):P274 doi:10.1186/1742-4690-6-S3-P274

This abstract is available from: http://www.retrovirology.com/content/6/S3/P274

Background

Emerging evidence indicates that HIV controllers contain HIV-1 replication through very active cellular immune responses, though how such responses can persist over time without exhaustion or waning is not yet understood. To investigate the nature of memory CD4+ T cells responsible for sustained anti-HIV responses, we characterized their capacity to generate primary cell lines specific for immunodominant Gag peptides.

Methods

CD4+ T cell lines were derived from patients who spontaneously controlled HIV replication (HIV controller group, n = 17) and patients who achieved viral control following successful antiretroviral therapy (HAART group, n = 20). Cell lines were compared for growth kinetics, Vβ repertoire, and sensitivity to antigen.

Results

Specific cell lines were obtained at high rate for both HIV controllers (16/17) and efficiently treated patients (19/20) in response to the immunodominant Gag293 peptide. However, lines from controllers showed faster growth kinetics than those of treated patients. After normalizing for growth rates, IFN-γ responses directed against the immunodominant Gag293 peptide showed higher functional avidity in HIV controllers, while responses to Gag161, Gag263, or CMV peptides did not differ between groups. Characterization of Gag293-specific CD4+ T cells through MHC class II tetramer labeling revealed a diverse Vβ repertoire, suggesting that multiple clones contributed to the high avidity CD4+ T cell population in HIV controllers. The high functional avidity of the Gag293-specific response could be explained, at least in part, by a high avidity interaction between the TCR and the peptide-MHC complex, as demonstrated by class II tetramer binding.

Conclusion

This study provides evidence that HIV controllers harbor a pool of high avidity memory CD4+ T cell precursors directed against an immunodominant Gag peptide. The capacity to mount a rapid CD4 response in the presence of minimal amounts of Gag antigen helps explain how HIV controllers maintain an active antiviral response in the face of very low viremia.